Technology Appraisal Committee Meeting (Committee C)

### Minutes: Confirmed

### Date and Time: Tuesday 4 August 2020 at 9:30am (Held via Zoom)

### Present:

* Steve O’Brien (Chair) Present for all items
* Peter Selby (Vice Chair) Present for all items
* Alex Cale Present for all items
* Michael Chambers Present for all items
* Prithwiraj Das Present for all items
* David Foreman Present for all items
* Rob Forsyth Present for all items
* Natalie Hallas Present for all items
* John Hampson Present for all items
* Nigel Langford Present for all items
* Andrea Manca Present for all items
* Iain McGowan Present for all items
* Kirandip Moyo Present for items 1 to 17
* Richard Nicholas Present for items 1 to 9 & 18 to 25
* Ugochi Nwulu Present for all items
* Stella O’Brien Present for all items
* Subhash Pokhrel Present for all items
* Andrew Renehan Present for all items
* Paul Tappenden Present for all items
* Derek Ward Present for all items

### In attendance:

* Ross Dent, Associate Director, NICE Present for items 1 to 9
* Jasdeep Hayre, Associate Director, NICE Present for items 10 to 25
* Louise Jafferally, Project Manager, NICE Present for all items
* Gavin Kenny, Project Manager, NICE Present for all items
* Richard Diaz, Technical Adviser, NICE Present for items 1 to 9
* Jamie Elvidge, Technical Adviser, NICE Present for items 18 to 25
* Victoria Kelly, Technical Adviser, NICE Present for items 10 to 17
* Cameron Collins, Technical Analyst, NICE Present for items 10 to 17
* Charlie Hewitt, Technical Analyst, NICE Present for items 1 to 9
* Verena Wolfram, Technical Analyst, NICE Present for items 18 to 25
* Rosalee Mason, Coordinator (MIP), NICE Present for all items
* Catherine Pank, Coordinator (MIP), NICE Present for all items
* Gemma Smith, Coordinator (COT), NICE Present for all items
* Ismahan Abdullah, Administrator, NICE Present for items 10 to 17
* Pratit Shah, Administrator Present for items 1-9 & 18-25
* Mandy Tonkinson, Public Involvement Adviser, NICE Present for items 1-6 & 10-14
* Lazaros Andronis, ERG representative, Warwick Evidence Present for items 1 to 6
* Daniel Gallacher, ERG representative, Warwick Evidence Present for items 1 to 6
* Mandana Zanganeh, ERG representative, Warwick Evidence Present for items 1 to 6
* Steve Edwards, ERG representative, BMJ Group Present for items 10 to 14
* Gemma Marceniuk, ERG representative, BMJ Group Present for items 10 to 14
* Victoria Wakefield, ERG representative, BMJ Group Present for items 10 to 14
* Lindsay Claxton, ERG representative, Centre for Reviews and Dissemination and

Centre for Health Economics – York Present for items 18 to 22

* Peter Clark, CDF Clinical Lead, NHS England Present for items 1 to 17
* Peter Hillmen, Clinical expert, Professor of Experimental Haematology Present for items 1 to 6
* Jackie Martin, Patient expert, Advocacy Officer, Present for items 1 to 6
* Kathryn Ryan, Clinical expert, Consultant Chemical Pathologist, Present for items 10 to 14
* Anna Schuh, Clinical expert, Associate Professor and Consultant Haematologist Present for items 1 to 6
* Simon Williams, Patient expert, Head of Communications & Policy, Heart UK Present for items 10 to 14
* Nick York, Patient expert, Patient Advocacy and Healthcare Liaison Officer , Present for items 1 to 6

### Non-public attendees:

* Helen Barnett, Senior Medical Editor, NICE Present for items 1 to 9
* Olivia Havercroft, Senior Medical Editor, NICE Present for items 10 to 17
* Sarah Bromley, Senior Medical Editor, NICE Present for items 18 to 25
* Gareth Murphy, Business Analyst, NICE Present for all items
* Sharmila Nebhrajani, NICE Chairman Present for all items
* Ben Purchase, Scientific Adviser, NICE Present for all items
* Thomas Strong, Technical Adviser, NICE Present for items 1 to 9
* Ross Wilkinson, Technical Analyst, NICE Present for items 10 to 25
* Rebecca Thomas, Technical Analyst, NICE Present for Items 10 to 17
* Suvi Härmälä, Technical Analyst, NICE Present for all items

### Notes

### Any other Business

1. None

### Appraisal of Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia [ID1402]

### Part 1 – Open session

1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from AbbVie.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests  
   1. Michael Chambers declared Financial Interests as he has recently been involved in running a training programme on Real World Evidence for Roche pharmaceuticals, manufacturer of a possible comparator therapy he confirmed this has not involved discussion of any specific Roche products.
      1. It was agreed that his declaration would not prevent Michael from participating in this section of the meeting.
   2. Richard Nicholas declared Non-Financial & Personal interests as he has attended advisory boards and undertaken trials using ocrelizumab (Roche) for multiple sclerosis.
      1. It was agreed that his declaration would not prevent Richard from participating in this section of the meeting.
   3. Prithwiraj Das declared a non-financial and personal interest as he works at Boehringer Ingelheim Ltd as Market Access Lead in Specialty Medicines (Oncology, Inflammation, Thrombolysis) in the UK & Ireland. He also confirmed he has not worked on any of the indications under investigation in the last 12 months.
      1. It was agreed that this declaration **would not** prevent Prithwiraj from participating on this topic.
3. No further conflicts of interest were declared for this appraisal.
4. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
5. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

**Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)**

1. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## Appraisal of Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]

### Part 1 – Open session

1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Esperion Therapeutics.
2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
   1. Prithwiraj Das declared a non-financial and personal interest as he works at Boehringer Ingelheim Ltd as Market Access Lead in Specialty Medicines (Oncology, Inflammation, Thrombolysis) in the UK & Ireland. He also confirmed he has not worked on any of the indications under investigation in the last 12 months.
      1. It was agreed that this declaration **would not** prevent Prithwiraj from participating on this topic.
3. No further conflicts of interest were declared for this appraisal.
4. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
5. The Chair asked the company representatives whether they wished to comment on any matters of factual inaccuracy.

**Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)**

1. The appraisal committee was unable to develop recommendations without the submission of additional analyses from the company.
2. The committee decision was based on consensus.
3. The committee asked NICE to pause this appraisal pending further analyses being completed.

**Appraisal of Selective internal radiation therapies (SIRT) for treating hepatocellular carcinoma [ID1276]**

**Part 1 – Open session**

1. The chair welcomed the external group representative, members of the public and company representatives from BTG, SIRTEX & Terumo Europe.
2. The chair asked all committee members, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
   1. Prithwiraj Das declared a non-financial and personal interest as he works at Boehringer Ingelheim Ltd as Market Access Lead in Specialty Medicines (Oncology, Inflammation, Thrombolysis) in the UK & Ireland. He also confirmed he has not worked on any of the indications under investigation in the last 12 months.
      1. It was agreed that this declaration **would not** prevent Prithwiraj from participating on this topic.
3. No further conflicts of interest were declared for this appraisal.
4. The Chair introduced the presentations on the clinical effectiveness and cost effectiveness of the treatment.
5. The Chair asked the company representatives whether they wished to comment on any matters of factual inaccuracy.

**Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)**

1. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

The next meeting of the Technology Appraisal (Committee C) will be held on Tuesday 1 September 2020 and will start promptly at 9:30am. The meeting will be held at Via Zoom.